Literature DB >> 650006

Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds.

H C Neu.   

Abstract

The pharmacokinetic properties of cefamandole were determined and compared with the properties of other cephalosporin agents. Cefamandole was found to be approximately 70% bound to protein. The mean peak concentration in serum after intramuscular (im) injection of 1 g of cefamandole was 20 microgram/ml at 0.5 hr, whereas the level at 6 hr was 1 microgram/ml. After intravenous (iv) infusion of 1 g of cefamandole, levels in serum ranged from 68 to 147 microgram/ml depending on the period of infusion. At 4 hr after infusion, levels were less than 1 microgram/ml. Probenecid elevated serum levels and prolonged excretion. The half-life (t1/2) of cefamandole after im injection ranged from 1 to 1.5 hr and from 0.45 to 1.2 hr after iv injection. Rates of serum and renal clearance of cefamandole ranged from 210 to 300 microliter/min per 1.73 m2. The apparent volume of distribution ranged from 12.4 to 17.9 liters/1.73 m2. Urinary excretion was rapid, with 60% of a dose excreted in the first 2 hr after injection. In 6 hr 90% of a dose was excreted. The pharmacokinetic properties of cefamandole were similar to those of cephalothin and cefoxitin, but the serum t1/2 was shorter than that reported for cefazolin and cefuroxime. Correlation of in vitro studies with pharmacokinetic properties revealed that cefamandole would inhibit most susceptible gram-positive and gram-negative bacteria if given by suggested im or iv regimens.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 650006     DOI: 10.1093/infdis/137.supplement.s80

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Forecasting cephalosporin and monobactam antibiotic half-lives in humans from data collected in laboratory animals.

Authors:  J Mordenti
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

2.  Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers.

Authors:  J N Parsons; J M Romano; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

3.  Newer antibiotics.

Authors:  A Kumar
Journal:  Indian J Pediatr       Date:  1981 Sep-Oct       Impact factor: 1.967

4.  The use of cefotaxime in the treatment of gram-positive pneumonias.

Authors:  S G Jenkinson
Journal:  Infection       Date:  1985       Impact factor: 3.553

5.  Bactericidal activities of chloramphenicol and eleven other antibiotics against Salmonella spp.

Authors:  S R Preblud; C J Gill; J M Campos
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

6.  Moxalactam therapy of serious infections.

Authors:  P Van der Auwera; N Clumeck; Y Van Laethem; R Vanhoof; J P Butzler
Journal:  Infection       Date:  1983 Jul-Aug       Impact factor: 3.553

7.  Cephalosporins: recent developments.

Authors:  A Kumar
Journal:  J Natl Med Assoc       Date:  1983-02       Impact factor: 1.798

8.  Pharmacology, Safety, and efficacy of cefamandole in childhood infections.

Authors:  M C Thirumoorthi; A S Dajani; C V Vincent; M J Maurer
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

9.  Cefamandole therapy in anaerobic infections.

Authors:  R N Greenberg; M C Scalcini; C V Sanders; A C Lewis
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

10.  Pharmacokinetics of intravenous cefmetazole with emphasis on comparison between predicted theoretical levels in tissue and actual skin window fluid levels.

Authors:  J S Tan; S J Salstrom; S A Signs; H E Hoffman; T M File
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.